子宫内膜癌中基于免疫组化筛查林奇综合征是否有效?知情同意是关键
该研究通过模拟模型评估基于免疫组化(IHC)方案在子宫内膜癌(EC)患者中识别林奇综合征(LS)索引病例的失败率,模型基于系统综述、聚焦综述、本地数据和专家意见构建,虚拟队列代表2018年美国预期诊断为EC的女性人数。结果显示IHC方案失败率最佳估计为58%(最低33%,最高80%),主要驱动因素为测序知情同意失败率高(25%至80%)。当模型中将测序知情同意率固定为25%、50%和80%时,索引病例识别失败的预期范围分别为78%-82%、57%-64%和29%-42%。结论认为知情同意是识别索引病例失败的主要驱动因素,且自美国LS筛查项目实施以来同意率改善甚微,这些高失败率难以大幅改善,错失的机会将因家系成员携带者状态的级联筛查无法进行而放大。
要点
- IHC筛查方案识别LS索引病例的失败率最佳估计为58%(范围33%-80%)。
- 测序知情同意失败率高达25%-80%,是方案失败的主要驱动因素。
- 同意率固定为25%、50%、80%时,识别失败范围分别为78%-82%、57%-64%、29%-42%。
核心结论
- 识别索引病例失败的主要驱动因素仍是测序知情同意,自美国LS筛查项目实施以来同意率改善甚微,这些高失败率难以大幅改善。
- 错失的机会将因家系成员携带者状态的级联筛查无法进行而放大。
研究设计与样本
- 研究构建了IHC方案的模拟模型,模型数据来自系统综述和聚焦综述,并辅以本地数据和专家意见。
- 虚拟队列代表2018年美国预期诊断为子宫内膜癌的女性人数。
主要发现
- IHC方案失败率的最佳估计为58%,最低和最高估计分别为33%和80%。
- 失败率主要驱动因素为测序知情同意失败率高(25%至80%)。
- 方案中多种不完美检测和潜在失败点合计占总体失败率的7%至20%。
- 当测序知情同意率固定为25%、50%和80%时,索引病例识别失败的预期范围分别为78%-82%、57%-64%和29%-42%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the plausible failure rate of the immunohistochemistry (IHC)-based screening protocol to identify Lynch syndrome (LS) index cases among endometrial cancer (EC) patients. METHODS: We developed a simulation model of the IHC protocol in this context. The model was populated from systematic and focused reviews, augmented with local data and expert opinion. The virtual cohort represents the number of women expected to be diagnosed with EC in the U.S. in 2018. The outcomes include protocol failure rates and LS cases missed in a variety of hypothetical scenarios. RESULTS: The best estimate of failure rate of the IHC protocol is 58%; minimum and maximum estimates are 33% and 80%, respectively. These failure rates are driven primarily by the high rates of failure to obtain consent from patients for sequencing (25% to 80%). The multiple imperfect tests and potential failure points in this protocol, collectively, make up 7% to 20% of the total failure rate. When consent for sequencing was fixed in the model at 25%, 50%, and 80%; the expected ranges for index case identification failure are 78%-82%, 57%-64%, and 29%-42%, respectively. CONCLUSION: The primary driver of failure to identify index cases remains consent for sequencing. Consent rates have shown little improvement since LS screening programs were instituted in the U.S., leaving us to conclude these high failure rates are resistant to substantial improvement. These missed opportunities will be magnified because cascade screening for carrier status among family members will not be pursued.
引用
- Gudgeon JM, Varner MW, Hashibe M, et al. Is immunohistochemistry-based screening for Lynch syndrome in endometrial cancer effective? The consent's the thing. Gynecol Oncol. 2019. PMID: 31130287. doi:10.1016/j.ygyno.2019.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。